Browsing by Author Ackland, Stephen P.

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 11 of 11
Issue DateTitleAuthor(s)Citation
2012Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: a subgroup analysis from the AGITG MAX trial: an international randomised controlled trial of Capecitabine, Bevacizumab and Mitomycin CSimes, Robert John; Tebbutt, Niall; Wilson, Catherine; Zannino, Diana; Ackland, Stephen P.; Broad, A; Cassidy, J; Ganju, V.; Price, Timothy; Robinson, B; Van Hazel, Guy Arthur; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: Public Health; School of Public Health: NH&MRC Clinical Trials CentreBevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: a subgroup analysis from the AGITG MAX trial: an international randomised controlled trial of Capecitabine, Bevacizumab and Mitomycin C, Annals of Oncology, vol.23, 6, 2012,pp 1531-1536
2010Capecitabine, Bevacizumab and Mitomycin in First-Line Treatment of Metastatic Colorectal Cancer: Results of the Australasian Gastrointestinal Trials Group Randomized, Phase III MAX Study.Gebski, Val; Simes, Robert John; Stockler, Martin; Zannino, Diana; Ackland, Stephen P.; Broad, Adam; Chua, Yu Jo; Cummins, Michelle; Cunningham, David; Forgeson, Garry; Ganju, Vinod; Price, Timothy; Robinson, Bridget; Saunders, M; Tebbutt, Niall C; van Hazel, Guy; Wilson, Kate; Zalcberg, J; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreCapecitabine, Bevacizumab and Mitomycin in First-Line Treatment of Metastatic Colorectal Cancer: Results of the Australasian Gastrointestinal Trials Group Randomized, Phase III MAX Study., Journal of Clinical Oncology (Online), vol.28, 19,pp 3191-3198
2007Concordance with national guidelines for colorectal cancer care in New South Wales: a population-based patterns of care studyArmstrong, Bruce; Chapuis, Pierre; Kneebone, Andrew; O'Connell, Dianne; Solomon, Michael; Young, Jane; Ackland, Stephen P.; Armstrong, Katie; Leong, David C.; Spigelman, Allan D; School of Public Health: Public Health; Concord Clinical School: Surgery; Central Clinical School: Surgery; Health Sciences Faculty Office; Central Clinical School: Surgery; School of Public Health: Public HealthConcordance with national guidelines for colorectal cancer care in New South Wales: a population-based patterns of care study, Medical Journal of Australia, vol.186,(6),2007,pp 292-295
2013Current opinion on optimal treatment for colorectal cancerPavlakis, Nick; Ackland, Stephen P.; Burge, Matthew; Cunningham, David; Haller, Daniel; Karapetis, Christos; Price, Timothy; Segelov, Eva; Shapiro, Jeremy; Sobrero, Alberto; Tebbutt, Niall C; Northern Clinical School: MedicineCurrent opinion on optimal treatment for colorectal cancer, Expert Review of Anticancer Therapy, vol.13, 5, 2013,pp 597-611
2010Fixed-dose-rate gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomasBrown, Christopher; Gainford, Mary; Gebski, Val; Miller, Danielle; Abdi, Ehtesham A; Ackland, Stephen P.; Goldstein, D; Jefford, Michael; Selva-Nayagam, Sid; Shannon, Jenny; Tebbutt, Niall C; van Hazel, Guy; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreFixed-dose-rate gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas, Cancer Chemotherapy and Pharmacology, vol.0, 0,pp 1-7
2012The GOFURTGO Study: AGITG Phase II Study of fixed dose rate gemcitabine-oxaliplatin integrated with concomitant 5FU and 3-D conformal radiotherapy for the treatment of localised pancreatic cancerBrown, Christopher; Gebski, Val; Horvath, Lisa; Hruby, George; Ackland, Stephen P.; Borg, M; Carroll, Susan; Cummins, Michelle M; et al, Various; Goldstein, David; Selva-Nayagam, Sid; Shapiro, Jeremy; Spry, Nigel.A.; van Hazel, Guy; Wratten, C.; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; Central Clinical School: Medicine; Central Clinical School: MedicineThe GOFURTGO Study: AGITG Phase II Study of fixed dose rate gemcitabine-oxaliplatin integrated with concomitant 5FU and 3-D conformal radiotherapy for the treatment of localised pancreatic cancer, British Journal of Cancer, vol.106, 1, 2012,pp 61-69
2002Phase I and pharmacokinetic study of docetaxel in combination with epirubicin and cyclophosphamide in advanced cancer: dose escalation possible with granulocyte colony-stimulating factor, but not with prophylactic antibodiesClarke, Stephen; Millward, Michael; Ackland, Stephen P.; Garg, M. B.; Rischin, D.; Smith, J.; Toner, Guy C.; Zalcberg, John; Concord Clinical School: ANZAC Research Institute; MedicinePhase I and pharmacokinetic study of docetaxel in combination with epirubicin and cyclophosphamide in advanced cancer: dose escalation possible with granulocyte colony-stimulating factor, but not with prophylactic antibodies, Annals of Oncology, vol.13,(11),2002,pp 1810-1818
2002Phase II trial of pemetrexed disodium (ALIMTA[R], LY231514) in chemotherapy-naive patients with advanced non-small-cell lung cancerBoyer, Michael; Clarke, Stephen; Millward, Michael; Abratt, R.; Ackland, Stephen P.; Goedhals, L.; Central Clinical School: Medicine; Concord Clinical School: ANZAC Research Institute; MedicinePhase II trial of pemetrexed disodium (ALIMTA[R], LY231514) in chemotherapy-naive patients with advanced non-small-cell lung cancer, Annals of Oncology, vol.13,(5),2002,pp 737-741
2009Phase IV Study of Bevacizumab in Combination with Infusional Fluorouracil, Leucovorin and Irinotecan (FOLFIRI) in First-Line Metastatic Colorectal CancerClarke, Stephen; Ackland, Stephen P.; Chiara, S.; Gapski, John; Langer, Bernd; Mainwaring, Paul; Perez-Carrion, Ramon; Sobrero, Alberto; Young, Scott; Concord Clinical School: ANZAC Research InstitutePhase IV Study of Bevacizumab in Combination with Infusional Fluorouracil, Leucovorin and Irinotecan (FOLFIRI) in First-Line Metastatic Colorectal Cancer, Oncology, vol.77, 2,pp 113-119
2006Predictors of Vinorelbine Pharmacokinetics and Pharmacodynamics in Patients With CancerBlair, Elaine; Clarke, Christine; Farlow, David; Gurney, Howard; Hoskins, Janelle; Mann, Graham; McLachlan, Andrew; Rivory, Laurent; Ackland, Stephen P.; Balleine, Rosemary; Collins, Michael; Evans, Scott; Garg, M. B.; WONG, Mark; Pharmacy; Western Clinical School: Westmead Millennium Institute; Western Clinical School: Imaging; Western Clinical School: Medicine (Westmead); School of Medical Sciences: Pharmacology; Western Clinical School: Westmead Millennium Institute; Pharmacy; Central Clinical School: MedicinePredictors of Vinorelbine Pharmacokinetics and Pharmacodynamics in Patients With Cancer, JOURNAL OF CLINICAL ONCOLOGY 2005, vol.24,(16),2006,pp 2448-2455
2006A randomized trial of capecitabine given intermittently versus continuously versus classical CMF as first line chemotherapy for women with advanced breast cancer unsuited to more intensive treatmentCoates, Alan; Gebski, Val; Simes, Robert John; Sourjina, Tatiana; Stockler, Martin; Ackland, Stephen P.; Byrne, Michael J.; Finch, K; Fitzharris, B; Forbes, John F.; Frances, P; Harvey, V; Kato-Fong, A; Lindsay, Dianne; Paksec, Lisa; van Hazel, Guy; School of Public Health: Public Health; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreA randomized trial of capecitabine given intermittently versus continuously versus classical CMF as first line chemotherapy for women with advanced breast cancer unsuited to more intensive treatment, Breast Cancer Research and Treatment, vol.100, Supplement 1,pp S278-S278